Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT1 | Q96EB6 | 12/20 | 0.51 |
| ▸ | SIRT2 | Q8IXJ6 | 13/20 | 0.49 |
| ▸ | SIRT5 | Q9NXA8 | 6/20 | 0.49 |
| ▸ | SIRT3 | Q9NTG7 | 4/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9488093 | 1.00 | SIRT1 (0.51) | SIRT1SIRT2SIRT5SIRT3 | |
| SCHEMBL1074473 | 0.95 | SIRT1 (0.47) | SIRT1SIRT2SIRT5SIRT3 | |
| SCHEMBL9489607 | 0.89 | SIRT2 (0.44) | SIRT1SIRT2SIRT5SIRT3 | |
| SCHEMBL9489620 | 0.89 | SIRT2 (0.44) | SIRT1SIRT2SIRT5SIRT3 | |
| SCHEMBL6696292 | 0.88 | PTGER4 (0.46) | SIRT1SIRT2SIRT5SIRT3 | |
| SCHEMBL9614367 | 0.87 | NPY4R (0.42) | — | |
| SCHEMBL29985699 | 0.86 | SIRT1 (0.54) | SIRT1SIRT2SIRT3 | |
| SCHEMBL1803249 | 0.86 | SIRT5 (0.54) | SIRT1SIRT2SIRT5SIRT3 | |
| SCHEMBL28595330 | 0.85 | KDM4E (0.38) | SIRT1SIRT2 | |
| SCHEMBL28595326 | 0.85 | KDM4E (0.38) | SIRT1SIRT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110092484-A1 | THERAPEUTIC OR PROPHYLACTIC AGENT FOR CEREBRAL ANEURYSM | NIPPON CHEMIPHAR CO., LTD. (JP) | 2011-04-21 | — | — | US | disclosed |
| EP-2168600-A1 | THERAPEUTIC OR PROPHYLACTIC AGENT FOR CEREBRAL ANEURYSM | Nippon Chemiphar Co., Ltd. (JP) | 2010-03-31 | — | — | EP | disclosed |
| EP-0255341-B1 | REAGENT FOR TESTING PERIODONTAL DISEASES | SUNSTAR KABUSHIKI KAISHA (JP) | 1993-02-03 | — | — | EP | disclosed |
| US-5137811-A | Method for diagnosing periodontal diseases with a substrate specific for aminopeptidase activity of periodontopathic bacteria | SUNSTAR KABUSHIKI KAISHA (JP) | 1992-08-11 | — | — | US | disclosed |
| EP-0255341-A2 | Reagent for testing periodontal diseases | SUNSTAR KABUSHIKI KAISHA (JP) | 1988-02-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092484-A1 | THERAPEUTIC OR PROPHYLACTIC AGENT FOR CEREBRAL ANEURYSM | SERPINB1, ECE1, MME | SIRT1 833/4885SIRT2 946/4885SIRT5 629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.